HeartFlow, Inc. is recommended as a buy due to its AI-enabled platform that enhances coronary artery disease diagnosis through tools like FFRCT and Plaque Analysis. The latter is validated and soon to have its own billing code, expanding the market and revenue from existing scans. With only about 2% market penetration and 41% year-over-year revenue growth, HeartFlow shows significant long-term growth potential despite risks. The current valuation of roughly 8.4 times forward revenue is considered justified by the company's expanding product suite and clinical integration.
Empery Digital's shares increased following the company's sale of Bitcoin assets. The funds raised will be used to support the development of a new AI data center project. This move highlights Empery Digital's strategic shift towards expanding its AI...
PepsiCo, a global leader in snacks and beverages, is currently trading near its 52-week low and offers a dividend yield of over 4%. Despite volume declines in North America due to pricing and consumer challenges, its international segments are drivin...
BNB Agent Studio launched on July 1, 2026, allowing developers to deploy autonomous AI agents on BNB Smart Chain in under 15 minutes using AWS Bedrock AgentCore for persistent cloud hosting. This platform simplifies the complex setup previously requi...
Virtual Protocol (VIRTUAL) saw its price surge 15.92% in 24 hours following a $700 million token migration to Chainlink’s Cross-Chain Interoperability Protocol, enhancing security after recent DeFi exploits. The project also integrated with Robinhood...
Kraft Heinz is rated Strong Buy due to its attractive 6.4% dividend yield and undervaluation at $25 per share. Positive technical momentum since June, including a golden cross formation, supports upside potential. Additional bullish factors include i...
